BMO Capital Initiates Coverage On Neurogene With Outperform Rating, Announces Price Target of $65
BMO Capital Initiates Coverage On Neurogene With Outperform Rating, Announces Price Target of $65
BMO Capital發佈評級，給予神經元股票超越市場的評級，宣佈價格目標爲65美元。
BMO Capital analyst Keith Tapper initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target of $65.
BMO Capital的分析師Keith Tapper通過給出65美元的目標價和發出超越市場評級，開始對Neurogene（NASDAQ: NGNE）進行覆蓋。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。